Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development
Back

Mindset Pharma Has Commenced Pre-Clinical Preparations For Novel Psychedelic Therapies

Jun 2, 2020 • 8:21 AM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Mindset Pharma is a psychedelic-based drug discovery business focused on creating novel, patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. The company is focused exclusively on novel and best in class psychedelics and is an opportunity that captured our attention.

In 2019, the company was founded by serial entrepreneurs and experts in drug development and medicinal chemistry. We are impressed with how the story has advanced so far this year and have found that Mindset Pharma is an opportunity that we will continue to follow.

Mindset represents a multi-faceted growth opportunity and is assembling a proprietary library of intellectual property (IP) that is aimed at addressing chronic neuropsychiatric disorders. One of the ways that Mindset has been able to differentiate itself is through the development of the first biased 5- HT2A agonists that are able to activate the desired cellular signal pathway while avoiding side effects. Through this approach, the company should help explain the biological and therapeutic effects and be able to design safer drugs.

Mindset will drive its drugs forward through two different approval pathways and we will monitor how the management team is able to execute on the strategy. The first pathway is through novel drug applications for new chemical entities (NCEs), which will ultimately require it to complete clinical trials. The second is a 505(b)2 pathway for drugs that combine already approved drugs. This strategy offers three years of IP protection as well as a faster approval process and does not require full clinical trials.

Commences Pre-Clinical Work on Novel Psychedelics

Last month, Mindset reported to have successfully synthesized approx. one-quarter of the target compounds that were identified in its previously filed patent applications, with another quarter of the compounds in late stages of synthesis. In the coming months, the company expects to complete the synthesis and will then start the pre-clinical screening process.

The compounds that were synthesized are derived from a set of novel compound structures that were designed by Mindset’s scientific team to create pharmaceutically superior next-generation psychedelic drugs to treat a range of neuropsychiatric indications. This represents an important development and comes less than a month after the business reported another significant milestone.

In April, Mindset reported to have started the pre-clinical work on the novel psychedelics that are identified in Mindset’s provisional patent applications (filed earlier this year). The company has identified several novel compound structures which it believes that it will facilitate the development of pharmaceutically appropriate next-generation psychedelic drugs to treat a range of neuropsychiatric indications.

Pharmaron, a premier R&D service company that supports the life science industry, will provide the initial compound synthesis and in-vitro screening to Mindset and we will monitor how the relationship supports the growth of the business.

Plans to Go Public in the Fourth Quarter of 2020

Mindset’s scientific team is working on a series of additional patent applications for novel psychedelic analogs and related manufacturing processes and is working on broadening the scope of their intellectual property assets. The team sees tremendous opportunities for both the composition of matter as well as process innovations in the psychedelic arena and we will monitor how it is able to execute on this.

In the fourth quarter of 2020, Mindset plans to complete a go-public transaction and has raised almost $1 million since inception. We believe that Mindset is an emerging opportunity and is one that our readers should be aware of.

If you are interested in learning more about Mindset Pharma, please send an email to support@mushroomstocks.com to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link